Jump to content

Licogliflozin

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Meodipt (talk | contribs) at 23:22, 7 July 2024. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Licogliflozin
Legal status
Legal status
  • Investigational
Identifiers
  • (2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-4-ethylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
CAS Number
PubChem CID
Chemical and physical data
FormulaC23H28O7
Molar mass416.470 g·mol−1
3D model (JSmol)
  • CCC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC4=C(C=C3)OCCO4
  • InChI=1S/C23H28O7/c1-2-14-4-5-15(23-22(27)21(26)20(25)19(12-24)30-23)11-16(14)9-13-3-6-17-18(10-13)29-8-7-28-17/h3-6,10-11,19-27H,2,7-9,12H2,1H3/t19-,20-,21+,22-,23+/m1/s1
  • Key:XFJAMQQAAMJFGB-ZQGJOIPISA-N

Licogliflozin is a drug which acts as an SGLT2 inhibitor. It was originally developed as a potential treatment for obesity,[1] but has also been investigated for other applications such as treating symptoms of polycystic ovary syndrome and nonalcoholic steatohepatitis.[2][3]

References

  1. ^ Zaki AM, Abo-Elnour DE, Abdalla YE, Hassan RY, Salama MK, Elboraay T, Abdelhaleem IA. Dose-dependent efficacy and safety of licogliflozin on obese adults: A systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr. 2022 Nov;16(11):102657. doi:10.1016/j.dsx.2022.102657 PMID 36335885
  2. ^ Tan S, Ignatenko S, Wagner F, Dokras A, Seufert J, Zwanziger D, Dunschen K, Zakaria M, Huseinovic N, Basson CT, Mahling P, Fuhrer D, Hinder M. Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial. Diabetes Obes Metab. 2021 Nov;23(11):2595-2599. doi:10.1111/dom.14495 PMID 34263971
  3. ^ Harrison SA, Manghi FP, Smith WB, Alpenidze D, Aizenberg D, Klarenbeek N, Chen CY, Zuckerman E, Ravussin E, Charatcharoenwitthaya P, Cheng PN, Katchman H, Klein S, Ben-Ari Z, Mendonza AE, Zhang Y, Martic M, Ma S, Kao S, Tanner S, Pachori A, Badman MK, He Y, Ukomadu C, Sicard E. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nat Med. 2022 Jul;28(7):1432-1438. doi:10.1038/s41591-022-01861-9 PMID 35725922
Retrieved from "https://en.wikipedia.org/w/index.php?title=Licogliflozin&oldid=1233224530"